SC 13G/A: China SXT Pharmaceuticals, Inc.

AI Summary

SC 13G/A filing by China SXT Pharmaceuticals, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.08 — ame of Issuer) COMMON STOCK, PAR VALUE $0.08PER SHARE (Title of Class of Securitie

Filing Documents

• tm2416145d1_sc13ga.htm (SC 13G/A) — 49KB
• 0001104659-24-066985.txt ( ) — 50KB

(a). Name

Item 1(a). Name of Issuer: China SXT Pharmaceuticals Inc

(b). Address of Issuer’s Principal Executive Offices

Item 1(b). Address of Issuer’s Principal Executive Offices: 178 Taidong Road North TAIZHOU, JNG, 225300 China

(a). Name of Person Filing

Item 2(a). Name of Person Filing: Forsakringsaktiebolaget Avanza Pension

(b). Address

Item 2(b). Address of Principal Business Office or, if None, Residence: Box 1399 STOCKHOLM, 11139 SWEDEN

(c). Citizenship

Item 2(c). Citizenship: Forsakringsaktiebolaget Avanza Pension is a company organized under the laws of Sweden

(d). Title

Item 2(d). Title of Class of Securities: Common Stock, Par Value $0.08 per share

(e). CUSIP

Item 2(e). CUSIP Number: G2161P140 Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o) (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c) (c) Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c) (d) Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8) (e) Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E) (f) Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F) (g) Parent Holding Company or control person in accordance with §240.13d-1(b)(1)(ii)(G) (h) Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813) (i) Church plan that is excluded from the definition of an investment company under §3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3) (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J) (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K) CUSIP No.: G2161P140 SCHEDULE 13G Page 4 of 6 Pages

Ownership

Item 4. Ownership. (a) Amount beneficially owned: 30,679 (b) Percent of class: 5,42 % (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 30,679 (ii) Shared power to vote or to direct the vote: None (iii) Sole power to dispose or to direct the disposition of: None (iv) Shared power to dispose or to direct the disposition of: 30,679 Number and Percentage of Shares Beneficially Owned Date 5,42 % / 30,679 May 30, 2024

Ownership

Item 5. Ownership of Five Percent or Less of a Class. Not applicable

Ownership

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. CUSIP No.: G2161P140 SCHEDULE 13G Page 5 of 6 Pages

Identification

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable

Identification

Item 8. Identification and Classification of Members of the Group. Not applicable

Notice

Item 9. Notice of Dissolution of Group. Not applicable CUSIP No.: G2161P140 SCHEDULE 13G Page 6 of 6 Pages

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a Swedish insurance company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. SIGNATURE After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct. May 31, 2024 Joakim Lomell / Middle Office Name/Title

View Full Filing

View this SC 13G/A filing on SEC EDGAR